Kilitch Drugs Issues EGM Corrigendum on Subsidiary Debt Conversion Share Allotment
Kilitch Drugs India Ltd 路 Extra Ordinary General Meeting 路 13 Nov 2026, 12:54 am
Kilitch Drugs Issues EGM Corrigendum on Subsidiary Debt Conversion Share Allotment Kilitch Drugs (India) issued a corrigendum on 12th Nov'26 for its EGM scheduled on 16th Nov'26, rectifying a typographical error regarding its material subsidiary, Kilitch Estro Biotech PLC (KEB). Pursuant to outstanding debt conversion, the company will be allotted 1,66,471 additional equity shares in KEB (corrected from 1,66,472), raising its stake from 67% to 89.17%. The entire shareholding will be sold to HarmeeCare Pharmaceuticals for a total consideration of USD 12.855 mn. All other terms of the EGM notice dated 22nd Oct'26 remain unchanged.
Original exchange filing (PDF)
More announcements from Kilitch Drugs India Ltd
- We are submitting Scrutinizer''s Report for evoting of EGM 路 16 Nov 2026
- Proceeding of EGM held today i.e. 16th November, 2026 路 16 Nov 2026
- We are submitting herewith the rectification of typo error in the outcome of Board meeting dated 22nd October, 2026 路 13 Nov 2026
- We are submitting herewith the outcome of the Board meeting 路 07 Nov 2026
- Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 07 Nov 2026
- Submitting unaudited financials results for quarter ended 30.09.2026 路 07 Nov 2026
- KILITCH DRUGS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 06 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 06 Nov 2026
